Evidence map›Paper›PMID 38137585›Full record

ReviewJournal of clinical medicine2023

Primary Anaplastic-Lymphoma-Kinase-Positive Large-Cell Lymphoma of the Central Nervous System: Comprehensive Review of the Literature.

Antonio Colamaria, Augusto Leone, Francesco Carbone, Yasser Andres Dallos Laguado, Nicola Pio Fochi, Matteo Sacco, Cinzia Fesce, Francesca Sanguedolce, Guido Giordano, Giorgio Iaconetta and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Case report: diagnostic challenges of primary central nervous system anaplastic large cell lymphoma, ALK-positive.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Antonio ColamariaDivision of Neurosurgery, Policlinico "Riuniti", 71122 Foggia, Italy.ORCID 0000-0003-0912-8484
Augusto LeoneDepartment of Neurosurgery, Städtisches Klinikum Karlsruhe, 76133 Karlsruhe, Germany.ORCID 0000-0002-4737-067X
Francesco CarboneDepartment of Neurosurgery, Städtisches Klinikum Karlsruhe, 76133 Karlsruhe, Germany.ORCID 0000-0002-6351-9999
Yasser Andres Dallos LaguadoFaculty of Medicine and Surgery, University of Foggia, 71122 Foggia, Italy.
Nicola Pio FochiDivision of Neurosurgery, University of Foggia, 71122 Foggia, Italy.
Matteo SaccoDivision of Neurosurgery, "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Cinzia FesceHematology Unit, University Hospital, 71122 Foggia, Italy.
Francesca SanguedolcePathology Unit, Ospedali Riuniti di Foggia, 71122 Foggia, Italy.
Guido GiordanoUnit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
Giorgio IaconettaUnit of Anatomy, Pathological Histology and Diagnostic Cytology, Department of Diagnostic and Pharma-Ceutical Services, Sandro Pertini Hospital, 00157 Rome, Italy.
Uwe SpetzgerDepartment of Neurosurgery, Städtisches Klinikum Karlsruhe, 76133 Karlsruhe, Germany.ORCID 0000-0001-5201-5202
Luigi CoppolaUnit of Anatomy, Pathological Histology and Diagnostic Cytology, Department of Diagnostic and Pharma-Ceutical Services, Sandro Pertini Hospital, 00157 Rome, Italy.
Elena De SantisDepartment of Anatomical, Histological, Forensic Medicine and Orthopedic sciences, La Sapienza University, 00185 Roma, Italy.ORCID 0000-0001-6415-6969
Giulia CoppolaDepartment of Radiological, Oncological and Pathological Sciences, La Sapienza University, 00185 Roma, Italy.
Matteo De NotarisDepartment of Neurosurgery, University of Salerno, 84084 Salerno, Italy.ORCID 0000-0002-4008-9092

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary anaplastic-lymphoma-kinase (ALK)-positive large-cell lymphoma of the central nervous system (PCNS ALK-positive ALCL) is a rare entity, with a limited consensus reached regarding its management. While this pathology often presents as solitary lesions, the occurrence of multiple tumors within the brain is not uncommon. The lack of distinctive radiological features poses a diagnostic challenge, leading to delays in initiating targeted therapy.

methodsWe conducted a comprehensive literature search, identifying seventeen publications for qualitative analysis.

resultsThe management options and reported patient outcomes in the literature varied significantly, emphasizing the need for a patient-specific approach. The emergence of ALK-specific inhibitors represents a new frontier in this field, demonstrating promising results.

conclusionPCNS ALK-positive ALCL necessitates a comprehensive understanding and optimized management strategies. A tailored therapeutic approach, integrating surgical intervention with radiotherapy and chemotherapy, appears pivotal in addressing this pathology. The implementation of a therapeutic protocol is anticipated for further advancement in this field.

Indexed as

ALKanaplastic large-cell lymphomaCD-30Ki-1primary central nervous system lymphoma

Identifiers

PMID38137585
PMCPMC10743784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.